Elicio Therapeutics, Inc. filed a Form 8-K on November 13, 2026, reporting the final voting results from its 2026 annual meeting of stockholders held on November 12, 2026.

Key Highlights

  • Quorum reached: Holders of 18,081,914 shares voted, constituting 66.74% of the voting power of all shares entitled to vote.
  • Three directors elected: Julian Adams, Ph.D., Jay R. Venkatesan, M.D., and Carol Ashe were elected as Class III directors to serve until the 2029 annual meeting.
  • Adams vote totals: 12,071,187 shares voted for, 860,662 withheld, and 5,150,065 broker non-votes.
  • Venkatesan vote totals: 12,832,184 shares voted for, 99,665 withheld, and 5,150,065 broker non-votes.
  • Ashe vote totals: 12,287,304 shares voted for, 644,545 withheld, and 5,150,065 broker non-votes.
  • Auditor ratified: Baker Tilly US, LLP was ratified as independent registered public accounting firm for fiscal year ending December 31, 2026, receiving 18,015,041 votes for, 52,870 against, and 14,003 abstentions.

Elicio Therapeutics Stockholders Approve Both Proposals at 2026 Annual Meeting

According to the filing, Elicio Therapeutics, Inc. (NASDAQ:ELTX) held its 2026 annual meeting of stockholders on November 12, 2026, in Boston, Massachusetts. The company disclosed that stockholders considered two proposals, each described in detail in the proxy statement filed with the SEC on October 9, 2026. A total of 18,081,914 shares of common stock were represented, constituting 66.74% of the voting power of all shares entitled to vote, which the company reported represented a quorum.

Under Proposal 1, stockholders voted to elect three Class III director nominees to serve three-year terms expiring at the 2029 annual meeting. The filing reports that Julian Adams, Ph.D. received 12,071,187 votes for and 860,662 withheld; Jay R. Venkatesan, M.D. received 12,832,184 votes for and 99,665 withheld; and Carol Ashe received 12,287,304 votes for and 644,545 withheld. Each nominee had 5,150,065 broker non-votes recorded.

Under Proposal 2, stockholders voted to ratify the Audit Committee's selection of Baker Tilly US, LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The filing reports 18,015,041 votes for, 52,870 against, and 14,003 abstentions, with no broker non-votes recorded. The filing states that "each of the proposals received the necessary votes in favor to be adopted by the Company's stockholders at the Annual Meeting."

What Was Disclosed

Elicio Therapeutics disclosed the final vote tallies from its November 12, 2026 annual stockholder meeting, covering the election of three Class III directors and the ratification of Baker Tilly US, LLP as the company's auditor for fiscal year 2026. Both proposals passed.